Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX – Get Free Report) was the recipient of a significant increase in short interest in the month of June. As of June 30th, there was short interest totalling 12,900 shares, an increase of 148.1% from the June 15th total of 5,200 shares. Based on an average daily volume of 52,500 shares, the short-interest ratio is presently 0.2 days.
Wall Street Analysts Forecast Growth
Separately, Maxim Group lowered their target price on shares of Quoin Pharmaceuticals from $15.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, March 15th.
Check Out Our Latest Stock Analysis on Quoin Pharmaceuticals
Institutional Trading of Quoin Pharmaceuticals
Quoin Pharmaceuticals Stock Up 0.9 %
Quoin Pharmaceuticals stock traded up $0.01 during mid-day trading on Friday, hitting $0.66. The company had a trading volume of 28,483 shares, compared to its average volume of 313,174. Quoin Pharmaceuticals has a 1 year low of $0.57 and a 1 year high of $12.00. The business has a fifty day moving average of $0.69 and a 200 day moving average of $1.79. The stock has a market cap of $2.61 million, a price-to-earnings ratio of -0.09 and a beta of 1.97.
Quoin Pharmaceuticals (NASDAQ:QNRX – Get Free Report) last posted its earnings results on Thursday, May 9th. The company reported ($1.11) EPS for the quarter. Equities analysts anticipate that Quoin Pharmaceuticals will post -3.51 earnings per share for the current year.
Quoin Pharmaceuticals Company Profile
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.
Further Reading
- Five stocks we like better than Quoin Pharmaceuticals
- Insider Buying Explained: What Investors Need to Know
- Top 3 Beverage Stocks: Summer Earnings Reveal Key Trends
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- This Financial Stock’s Earnings Signal a Buying Opportunity
- Find and Profitably Trade Stocks at 52-Week Lows
- Social Platform Stock Hits New Highs: Is More Growth Ahead?
Receive News & Ratings for Quoin Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quoin Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.